Table 2.
Characteristics of outpatients infected with broad-spectrum cephalosporin-resistant K. oxytoca clinical isolatesa
| Isolate no. | Date of isolation (mo/yr) | Age (yr)/sex | Time after hospitalization (days) | Reason for previous hospitalization | Predisposing factor(s)/underlying disease | Previous consumption of antibioticsb | β-Lactamase gene | PFGE type |
|---|---|---|---|---|---|---|---|---|
| 1 | 1/2005 | 72/M | 15 | Renal lithiasis | Prostate cancer, diabetes mellitus | AMK, CXM | CMY-31, VIM-1 | Ia |
| 2 | 1/2005 | 77/F | 124 | Renal lithiasis | PTZ, CIP, CXM | CMY-31, VIM-1 | Ib | |
| 3 | 2/2005 | 79/M | 21 | Prostatectomy | Diabetes mellitus | PTZ, AMK, CXM | CMY-31, VIM-1 | Ia |
| 4 | 4/2005 | 71/M | 43 | Papillary transitional carcinoma | PIICA | TCA, CXM | CMY-31 | Ia |
| 5 | 5/2005 | 67/M | 12 | Prostate hypertrophy | PTZ, CIP | CMY-31 | Ia | |
| 6 | 1/2006 | 63/M | 197 | Renal lithiasis | PTZ, AMK, CIP | CMY-31 | Ia | |
| 7 | 9/2006 | 71/M | 18 | Papillary transitional carcinoma | PIICA | TCA, AMK | CMY-31 | Ic |
| 8 | 2/2007 | 82/M | 98 | Papillary transitional carcinoma | PIICA | TCA, CIP | CMY-31 | Id |
| 9 | 4/2007 | 68/F | 17 | Renal lithiasis | TCA, CXM | CMY-31 | Ie |
a
M, male; F, female; PIICA, previous intravesical instillation of chemotherapeutic agents; AMK, amikacin; CIP, ciprofloxacin; CXM, cefuroxime; PTZ, piperacillin-tazobactam; TCA, ticarcillin-clavulanate.
b
During previous hospitalization and/or after discharge.